Dr. Lang is a seasoned pharmaceutical executive with extensive drug development experience in large pharma and smaller biotechs. Originally trained as an Anesthesiologist and Pain Management Specialist, he has over 28 years of experience in the pharmaceutical industry. Eric has extensive experience in developing pain management drugs and hospital injectable/ICU medications. Throughout his pharmaceutical career, he has worked with both drug and device development programs in a large variety of additional therapeutic areas. Dr. Lang has experience in designing development programs from early translational stages through phase III including the successful filing of several recent INDs and NDAs. He has experience with Regulatory interactions and negotiations with FDA and various European and Asian Authorities.
Dr. Lang began his career with Johnson and Johnson, later worked for Novartis Consumer Health and then lead the clinical development team at Javelin Pharmaceuticals, which was ultimately acquired by Hospira (now Pfizer) in 2010. Following this acquisition, Dr. Lang joined Grunenthal USA as their head of clinical development. After Grunenthal, he joined Covance heading an international team that assisted smaller biotechs in moving their programs through the various phases of pre-clinical and clinical development. Following the acquisition of Covance by LabCorp, Eric transitioned to EnteraBio as Chief Medical Officer until joining Nevakar Inc, initially as Vice President of Clinical Development and later as Chief Medical Officer. In his most recent role, prior to joining Kinexium, Eric was the Chief Medical Officer for Chromocell Therapeutics, later named Channel Therapeutics where he supported their IPO and designed and led their clinical development programs.
In his spare time, Eric is a scuba diving instructor, enjoys travel and wood working.